PL2119778T3 - Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie - Google Patents

Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie

Info

Publication number
PL2119778T3
PL2119778T3 PL08712039T PL08712039T PL2119778T3 PL 2119778 T3 PL2119778 T3 PL 2119778T3 PL 08712039 T PL08712039 T PL 08712039T PL 08712039 T PL08712039 T PL 08712039T PL 2119778 T3 PL2119778 T3 PL 2119778T3
Authority
PL
Poland
Prior art keywords
helper
activation
cell
composition
Prior art date
Application number
PL08712039T
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Publication of PL2119778T3 publication Critical patent/PL2119778T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
PL08712039T 2007-02-27 2008-02-27 Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie PL2119778T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007047317 2007-02-27
PCT/JP2008/053417 WO2008105462A1 (ja) 2007-02-27 2008-02-27 ヘルパーｔ細胞の活性化方法およびそのための組成物
EP08712039.0A EP2119778B1 (en) 2007-02-27 2008-02-27 Method for activation of helper T cell and composition for use in the method

Publications (1)

Publication Number Publication Date
PL2119778T3 true PL2119778T3 (pl) 2016-04-29

Family

ID=39721287

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08712039T PL2119778T3 (pl) 2007-02-27 2008-02-27 Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie

Country Status (25)

Country Link
US (2) US10139395B2 (pl)
EP (1) EP2119778B1 (pl)
JP (2) JP5225262B2 (pl)
KR (1) KR101598228B1 (pl)
CN (6) CN103088103B (pl)
AU (1) AU2008220031B2 (pl)
BR (1) BRPI0808084A2 (pl)
CA (1) CA2677075C (pl)
CY (1) CY1117150T1 (pl)
DK (1) DK2119778T3 (pl)
ES (1) ES2559062T3 (pl)
HR (1) HRP20160020T1 (pl)
HU (1) HUE027472T2 (pl)
IL (1) IL200161A (pl)
MX (2) MX352947B (pl)
MY (2) MY158219A (pl)
NZ (3) NZ599160A (pl)
PL (1) PL2119778T3 (pl)
PT (1) PT2119778E (pl)
RU (2) RU2680539C2 (pl)
SG (1) SG177998A1 (pl)
SI (1) SI2119778T1 (pl)
UA (1) UA101608C2 (pl)
WO (1) WO2008105462A1 (pl)
ZA (1) ZA200905467B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101580538B (zh) 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
BRPI0808084A2 (pt) 2007-02-27 2014-07-22 Int Inst Cancer Immunology Inc Método para ativação de células t auxiliadoras e composição para uso no método.
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US8809050B2 (en) 2009-12-08 2014-08-19 Wilson Wolf Manufacturing Methods of cell culture for adoptive cell therapy
EP2626418B8 (en) 2010-10-05 2021-03-24 International Institute of Cancer Immunology, Inc. Method for activating helper t cell
AU2012309417B2 (en) * 2011-09-14 2017-09-14 International Institute Of Cancer Immunology, Inc. Method for measuring anti-WT1 antibody
US20140341939A1 (en) * 2011-12-14 2014-11-20 National University Corporation Kochi University Modification of helper t cell-inducing polypeptide
HK1204261A1 (en) 2012-01-13 2015-11-13 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
CN104797711B (zh) * 2012-09-12 2018-09-21 株式会社癌免疫研究所 抗原特异性辅助性t细胞受体基因
CA2892660C (en) 2012-12-17 2022-02-15 Otsuka Pharmaceutical Co., Ltd. Method for activating helper t cell
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
KR101804343B1 (ko) * 2014-02-26 2017-12-04 텔라 가부시키가이샤 Ｗｔ１ 항원성 폴리펩티드 및 상기 폴리펩티드를 포함하는 항종양제
CN108350411B (zh) 2015-06-25 2021-06-22 白川利朗 口服肿瘤疫苗
JP6810877B2 (ja) 2016-12-26 2021-01-13 国立大学法人神戸大学 経口腫瘍ワクチンと免疫抑制阻害剤との併用によるがん治療
WO2021138447A1 (en) 2019-12-31 2021-07-08 Elixirgen Therapeutics, Inc. Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
KR102647825B1 (ko) * 2021-07-22 2024-03-14 서울대학교산학협력단 항-hla-dp 단클론 항체 및 이의 용도
CN116559462A (zh) * 2023-04-12 2023-08-08 中国科学技术大学 用于肿瘤患者预后的生物标志物组及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
EP1103564B1 (en) 1998-07-31 2009-01-07 International Institute of Cancer Immunology, Inc. Cancer antigens based on tumor suppressor gene wt1 product
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
PL201881B1 (pl) 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CA2401070A1 (en) 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
BRPI0208183B8 (pt) 2001-03-22 2021-05-25 Sugiyama Haruo peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
CA2451846A1 (en) 2001-06-29 2003-01-09 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine comprizing a cancer antigen based on the product of a tumor suppressor gene wt1 and a cationic liposome
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003028758A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003028757A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
KR101050703B1 (ko) 2002-06-12 2011-07-20 추가이 세이야쿠 가부시키가이샤 Ｈｌａ-ａ24-구속성 암 항원 펩티드
ES2538486T3 (es) 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
WO2004026897A1 (ja) 2002-09-20 2004-04-01 Chugai Seiyaku Kabushiki Kaisha Ｗｔ１置換型ペプチド
US20060217297A1 (en) 2003-01-15 2006-09-28 Haruo Sugiyama Dimerized peptide
ES2443582T3 (es) 2003-06-27 2014-02-19 International Institute Of Cancer Immunology, Inc. Método para diagnosticar el cáncer que comprende la medición de las células precursoras de CTL específicos de WT1
CN101580538B (zh) * 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
US7488718B2 (en) * 2003-12-01 2009-02-10 Sloan Kettering Institue For Cancer Research Synthetic HLA binding peptide analogues and uses thereof
ES2556232T3 (es) 2004-03-31 2016-01-14 International Institute Of Cancer Immunology, Inc. Péptidos antigénicos del cáncer derivados de WT1
JP4719876B2 (ja) * 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
WO2007063903A1 (ja) 2005-11-30 2007-06-07 International Institute Of Cancer Immunology, Inc. 新規ペプチド化合物
PL1988163T3 (pl) 2006-02-22 2012-11-30 Int Inst Cancer Immunology Inc Ograniczony do hla-a*3303 peptyd wt1 i zawierająca go kompozycja farmaceutyczna
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
NZ601175A (en) 2006-12-28 2012-12-21 Int Inst Cancer Immunology Inc Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
BRPI0808084A2 (pt) 2007-02-27 2014-07-22 Int Inst Cancer Immunology Inc Método para ativação de células t auxiliadoras e composição para uso no método.
WO2008108257A1 (ja) 2007-03-05 2008-09-12 International Institute Of Cancer Immunology, Inc. 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
EP2626418B8 (en) 2010-10-05 2021-03-24 International Institute of Cancer Immunology, Inc. Method for activating helper t cell
CA2892660C (en) 2012-12-17 2022-02-15 Otsuka Pharmaceutical Co., Ltd. Method for activating helper t cell

Also Published As

Publication number Publication date
PT2119778E (pt) 2016-02-15
RU2014104572A (ru) 2015-08-20
ZA200905467B (en) 2010-05-26
CN103088103B (zh) 2015-09-30
EP2119778B1 (en) 2015-11-04
JP5714619B2 (ja) 2015-05-07
CN103103246B (zh) 2018-05-01
HRP20160020T1 (hr) 2016-02-12
US10139395B2 (en) 2018-11-27
UA101608C2 (uk) 2013-04-25
BRPI0808084A2 (pt) 2014-07-22
JPWO2008105462A1 (ja) 2010-06-03
SG177998A1 (en) 2012-02-28
EP2119778A1 (en) 2009-11-18
CA2677075A1 (en) 2008-09-04
CN104774910A (zh) 2015-07-15
US20100247556A1 (en) 2010-09-30
CN104312974A (zh) 2015-01-28
HK1138321A1 (en) 2010-08-20
RU2009135802A (ru) 2011-04-10
CA2677075C (en) 2018-07-10
MY158219A (en) 2016-09-15
RU2680539C2 (ru) 2019-02-22
NZ599161A (en) 2012-07-27
MX352947B (es) 2017-12-14
US20200064332A1 (en) 2020-02-27
HUE027472T2 (en) 2016-09-28
CN103088103A (zh) 2013-05-08
CN103149366A (zh) 2013-06-12
JP5225262B2 (ja) 2013-07-03
ES2559062T3 (es) 2016-02-10
DK2119778T3 (en) 2016-01-25
US11555814B2 (en) 2023-01-17
NZ599160A (en) 2012-07-27
IL200161A (en) 2015-11-30
EP2119778A4 (en) 2010-08-18
IL200161A0 (en) 2011-08-01
SI2119778T1 (sl) 2016-03-31
NZ578721A (en) 2012-04-27
CN103103246A (zh) 2013-05-15
AU2008220031A1 (en) 2008-09-04
CN101622344A (zh) 2010-01-06
JP2013139448A (ja) 2013-07-18
KR101598228B1 (ko) 2016-02-26
KR20090125067A (ko) 2009-12-03
WO2008105462A1 (ja) 2008-09-04
MX2009009168A (es) 2009-09-07
CN104312974B (zh) 2018-09-04
CN104774910B (zh) 2018-04-10
CN103149366B (zh) 2018-06-15
AU2008220031B2 (en) 2013-06-13
CY1117150T1 (el) 2017-04-05
MY164867A (en) 2018-01-30

Similar Documents

Publication Publication Date Title
ZA200905467B (en) Method for activation of helper T cell and composition for use in the method
IL267138A (en) Improved composition of cells and methods for its preparation
GB2443823B (en) Devices and methods for use in construction
SG10201605686XA (en) Polishing Composition And Polishing Method Using The Same
IL202329A0 (en) Methods and compositions for stimulating cells
EP2180933A4 (en) POROUS BODIES AND METHODS
ZA200905886B (en) Methods and kits for administering probiotics
IL205977A0 (en) 5-anilinoimidazopyridines and methods of use
EP2324956A4 (en) POLISHING COMPOSITION AND THIS USE POLISHING METHOD
IL206125A0 (en) Azaindolizines and methods of use
GB0709781D0 (en) Composition and method
EP2183335A4 (en) MICROPOSITION COMPOSITION AND USE METHOD THEREFOR
GB0724967D0 (en) Composition and method
GB0605702D0 (en) Materials and methods for immune cell stimulation
GB2442084B (en) Flow-through cell and method of use
GB0905971D0 (en) Antitussive composition and method for making the same
ZA201004894B (en) Nuctraceutical composition and methods of use
EP2115127A4 (en) METHOD AND COMPOSITIONS FOR IMPROVING CELL HEALTH IN CULTURES
GB0620930D0 (en) Composition and method for use thereof
ZA201004893B (en) Nuctraceutical composition and methods of use
ZA201008261B (en) Non-hydrating plaster composition and method
EP2348865A4 (en) BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES, THEIR METHODS OF PREPARATION AND THEIR USE
MY152929A (en) Polishing composition and polishing method
EP2185685A4 (en) NEW PROCESSES AND NEW CELL LINES
TWI365216B (en) Polishing composition for polishing lithium aluminate and method of using the same